Barinthus Biotherapeutics (BRNS) Enterprise Value (2020 - 2026)

Barinthus Biotherapeutics has reported Enterprise Value for 7 years, with the latest figure at -$67.1 million in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value rose 33.21% year-over-year to -$67.1 million; the trailing twelve-month figure through Mar 2026 stood at -$67.1 million (up 33.21% YoY), and the FY2025 full-year result was -$71.8 million, up 36.09% from the prior year.
• Enterprise Value for Q1 2026 stood at -$67.1 million, up from -$71.8 million in the prior quarter.
• The five-year high for Enterprise Value was $211000.0 in Q4 2023, with the low at -$200.2 million in Q1 2022.
• Historically, Enterprise Value has averaged -$128.1 million across 5 years, with a median of -$117.6 million in 2024.
• Annual changes were most pronounced in 2023 — Enterprise Value surged 100.11% — and 2024, when it slumped 53319.91%.
• Barinthus Biotherapeutics' Enterprise Value stood at -$194.1 million in 2022, then surged by 100.11% to $211000.0 in 2023, then tumbled by 53319.91% to -$112.3 million in 2024, then surged by 36.09% to -$71.8 million in 2025, then rose by 6.49% to -$67.1 million in 2026.
• The last three Enterprise Value figures came in at -$67.1 million (Q1 2026), -$71.8 million (Q4 2025), and -$75.6 million (Q3 2025), per Business Quant data.